CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer

Gootjes, Elske C.; Kraan, Jaco; Buffart, Tineke E.; Bakkerus, Lotte; Zonderhuis, Barbara M; Verhoef, Cornelis; Verheul, H.; Sleijfer, And Stefan

doi:10.3390/cells9010124

Cited by 5 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Ang-2 receptor, Tie-2 was also found to be expressed by stalk cells, while not detectable in tip cells [52]. Of note, tumor-associated circulating EnC were reported to overexpress CD276, an immune checkpoint molecule therefore being distinctive to normal circulating EnCs [64].…”

Section: Endothelial Cell General Backgroundmentioning

confidence: 95%

“…There are also studies dismissing biomarker usability of certain circulating EnC. Gootjes et al [64] investigated the CD267 positive circulating EnC (basic phenotype: CD34+/CD45neg/CD146+/DNA+) to predict therapy responsiveness to palliative systemic therapy in patients with metastatic colorectal cancer and reported inadequate prediction potential. Consequently, prognosis seems to remain the most valid biomarker application upon baseline measurement.…”

Section: Endothelial Cell Clinical Usementioning

confidence: 99%

See 1 more Smart Citation

The Blood Circulating Rare Cell Population. What Is It and What Is It Good for?

Schreier

Triampo

2020

Cells

View full text Add to dashboard Cite

Blood contains a diverse cell population of low concentration hematopoietic as well as non-hematopoietic cells. The majority of such rare cells may be bone marrow-derived progenitor and stem cells. This paucity of circulating rare cells, in particular in the peripheral circulation, has led many to believe that bone marrow as well as other organ-related cell egress into the circulation is a response to pathological conditions. Little is known about this, though an increasing body of literature can be found suggesting commonness of certain rare cell types in the peripheral blood under physiological conditions. Thus, the isolation and detection of circulating rare cells appears to be merely a technological problem. Knowledge about rare cell types that may circulate the blood stream will help to advance the field of cell-based liquid biopsy by supporting inter-platform comparability, making use of biological correct cutoffs and “mining” new biomarkers and combinations thereof in clinical diagnosis and therapy. Therefore, this review intends to lay ground for a comprehensive analysis of the peripheral blood rare cell population given the necessity to target a broader range of cell types for improved biomarker performance in cell-based liquid biopsy.

show abstract

Section: Endothelial Cell General Backgroundmentioning

confidence: 95%

Section: Endothelial Cell Clinical Usementioning

confidence: 99%

The Blood Circulating Rare Cell Population. What Is It and What Is It Good for?

Schreier

Triampo

2020

Cells

View full text Add to dashboard Cite

show abstract

“…CD276 (also called B7H3), a member of the B7/CD28 superfamily, was found to be expressed at high levels in multiple tumor types (4). Various cell types, such as endothelial cells, immune cells and osteoblasts, have also been reported to exhibit positive expression of CD276 (5). An the coinhibitory function of CD276 in immune cells has also been observed (6).…”

Section: Currently Immunotherapy Including Immune Checkpointmentioning

confidence: 99%

CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma

Yue¹,

Tang²,

Zhang³

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: As an immune checkpoint that suppresses antitumor immunity, CD276 is a potential therapeutic target for cancer immunotherapy. However, the role of CD276 in esophageal squamous cell carcinoma (ESCC) has not been thoroughly examined. A greater understanding of the regulatory mechanism of CD276 may improve the clinical response and efficacy of cancer immunotherapy. Methods: The expression of CD276 was measured by qRT-PCR, IHC and flow cytometry analysis. T cell infiltration in ESCC was measured by qRT-PCR and immunofluorescence analysis. The regulation function of CD276 in glucose metabolism was examined by metabolism assays, western blotting and small molecule inhibitors. Transfection was used for gene editing. The oncogenic function of CD276 was examined in vivo by CAR-T cell therapy model. Results: Based on our findings, CD276 regulated the expression of the PKM2 gene in ESCC.Overexpression of CD276 induced the phosphorylation of PKM2 by the STAT3 signalling pathway to promote glucose metabolism in tumors. The accumulation of lactic acid in the tumor microenvironment has been reported to regulate the immune cells, particularly CD8+ T cells. We further analyzed the effect of CD276 on the function of T cells. Chimeric antigen receptor T cells (CAR-T) targeting human epidermal growth factor receptor 2 (HER2) were used as effector cells to detect the effect of CD276 on immunotherapy. The therapeutic effects of CAR-T cells were markedly limited by CD276 overexpression. Conclusions: Our results are the first to show that tumor-derived CD276 supports disease progression.Overexpression of CD276 promoted glucose metabolism in tumor and inhibited the function of CD8+ T cells. Therefore, strategies targeting CD276 might improve the response to cancer immunotherapy of ESCC patients.

show abstract

“…Matsusaka et al discovered that CXCR4-positive CEC were significantly associated with longer PFS and OS as compared other indicators investigated [ 242 ]. Similarly, Gootjes et al observed that CECs and CD276-psoitive CTECs based on FCM were significantly increased after treatment with bevacizumab plus chemotherapy in mCRC patients [ 243 ]. To analyze CECs and their subpopulations, two analytical techniques are available: multiparameter FCM and the CellSearch system [ 237 ].…”

Section: Main Textmentioning

confidence: 99%

Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer

et al. 2022

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by the operator for clinical decisions. Because conventional tissue biopsy is invasive and only a small sample can sometimes be obtained, it is unable to represent the heterogeneity of tumor or dynamically monitor tumor progression. Therefore, there is an urgent need to find a new minimally invasive or noninvasive diagnostic strategy to detect CRC at an early stage and monitor CRC recurrence. Over the past years, a new diagnostic concept called “liquid biopsy” has gained much attention. Liquid biopsy is noninvasive, allowing repeated analysis and real-time monitoring of tumor recurrence, metastasis or therapeutic responses. With the advanced development of new molecular techniques in CRC, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and tumor-educated platelet (TEP) detection have achieved interesting and inspiring results as the most prominent liquid biopsy markers. In this review, we focused on some clinical applications of CTCs, ctDNA, exosomes and TEPs and discuss promising future applications to solve unmet clinical needs in CRC patients.

show abstract

CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer

Cited by 5 publications

References 22 publications

The Blood Circulating Rare Cell Population. What Is It and What Is It Good for?

The Blood Circulating Rare Cell Population. What Is It and What Is It Good for?

CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma

Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer

Contact Info

Product

Resources

About